Results 81 to 90 of about 25,503 (303)

Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy

ESC Heart Failure, Volume 12, Issue 2, Page 1029-1044, April 2025.
Abstract Cardiac remodelling is a key determinant of worse cardiovascular outcome in patients with heart failure (HF) and reduced ejection fraction (HFrEF). It affects both the left ventricle (LV) structure and function as well as the left atrium (LA) and the right ventricle (RV).
Giada Colombo, Tor Biering‐Sorensen, Joao P. Ferreira, Carlo Mario Lombardi, Andrea Bonelli, Andrea Garascia, Marco Metra, Riccardo M. Inciardi   +7 more
wiley   +1 more source

Increased Plasma Arginine Vasopressin in Clinical Adrenocortical Insufficiency and Its Inhibition By Glucosteroids* [PDF]

, 1967
Abdul Barik Ahmed, Barbara Crutchfield George, Carlos Gonzalez-Auvert, Joseph F. Dingman   +3 more
openalex   +1 more source

Effect of Adrenal steroid hormones on the response of the toad's urinary bladder to vasopressin [PDF]

, 1969
Jerome S. Handler, A S Preston, Jack Orloff   +2 more
openalex   +1 more source

Analysis of outcomes in patients with HeartMate 3 with and without right ventricular assist device support

ESC Heart Failure, EarlyView.
Temporary RVAD support following HM3 LVAD is associated with high morbidity and mortality. Temporary RVAD support occurs most frequently in INTERMACS 1 or 2 patients and those who require pre‐operative VA‐ECMO. In addition to higher post‐operative mortality, a significantly higher risk of both dialysis and stroke at 1 year post‐implant was observed in ...
Vinh Q. Chau, Laura Coyle, Rachel Pedersen, Colleen Gallagher, Nicole Graney, Lisa Kukla, Robin Paliga, Gregory P. Macaluso, Sunil Pauwaa, William G. Cotts, Patroklos S. Pappas, Antone J. Tatooles, Nikhil Narang   +12 more
wiley   +1 more source

Kinetic Analysis of the Antidiuretic Action of Vasopressin and Adenosine-3′,5′-Monophosphate * [PDF]

, 1964
Isidore S. Edelman, Martin J. Petersen, Paul F. Gulyassy   +2 more
openalex   +1 more source

Finerenone, glycaemic status, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS‐HF trial

European Journal of Heart Failure, EarlyView.
Finerenone and glycaemic status in patients with heart failure with mildly reduced/preserved ejection fraction. CI, confidence interval; CV, cardiovascular; HF, heart failure; HR, hazard ratio; RR, rate ratio. Abstract Aims The efficacy and safety of the non‐steroidal mineralocorticoid receptor antagonist, finerenone, have not been examined in patients
Jawad H. Butt, Pardeep S. Jhund, Alasdair D. Henderson, Brian L. Claggett, Akshay S. Desai, Carolyn S.P. Lam, Meike Brinker, Patrick Schloemer, Prabhakar Viswanathan, Andrea Lage, Katja Rohwedder, Michele Senni, Sanjiv J. Shah, Adriaan A. Voors, Faiez Zannad, Bertram Pitt, Muthiah Vaduganathan, Scott D. Solomon, John J.V. McMurray   +18 more
wiley   +1 more source

EFFECT OF OXYTOCIN, VASOPRESSIN, AND OTHER DISULFID HORMONES ON UPTAKE AND EXTRUSION OF WATER BY MITOCHONDRIA [PDF]

, 1961
Albert L. Lehninger, Diether Neubert
openalex   +1 more source

Vasopressin and Memory Consolidation

, 1976
Publisher Summary The hypothalamic-neurohypophyseal system possibly makes use of (a) the general circulation for peripheral effects of posterior pituitary hormones; (b) the portal vessel system for the regulation of anterior pituitary function; and (c) the cerebrospinal fluid for CNS activities.
Gispen, W.H., Wied, D. de, Wimersma Greidanus, T.B. van, Bohus, B., Urban, I.   +4 more
openaire   +3 more sources

Finerenone, chronic obstructive pulmonary disease, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS‐HF trial

European Journal of Heart Failure, EarlyView.
The beneficial effects of finerenone in patients with heart failure (HF) and mildly reduced or preserved ejection fraction were consistent, regardless of a history of chronic obstructive pulmonary disease (COPD) status. BMI, body mass index; LVEF, left ventricular ejection fraction; NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide.
Jawad H. Butt, Pardeep S. Jhund, Alasdair D. Henderson, Brian L. Claggett, Akshay S. Desai, Carolyn S.P. Lam, Katharina Mueller, Markus F. Scheerer, Prabhakar Viswanathan, Michele Senni, Sanjiv J. Shah, Adriaan A. Voors, Faiez Zannad, Bertram Pitt, Muthiah Vaduganathan, Scott D. Solomon, John J.V. McMurray   +16 more
wiley   +1 more source

The efficacy of finerenone on hierarchical composite endpoint analysed using win statistics in patients with heart failure and mildly reduced or preserved ejection fraction: A prespecified analysis of FINEARTS‐HF

European Journal of Heart Failure, EarlyView.
Effect of finerenone on a hierarchical endpoint. CI, confidence interval; CV, cardiovascular; EF, ejection fraction; HF, heart failure. ABSTRACT Aims FINEARTS‐HF demonstrated the efficacy of finerenone in reducing total worsening heart failure (HF) events (first and recurrent) and cardiovascular death, compared to placebo, in patients with HF and ...
Toru Kondo, Pardeep S. Jhund, Alasdair D. Henderson, Brian L. Claggett, Akshay S. Desai, Meike Brinker, James Lay‐Flurrie, Patrick Schloemer, Prabhakar Viswanathan, Flaviana Amarante, Chern‐En Chiang, Gerasimos Filippatos, Carolyn S.P. Lam, Mark C. Petrie, Michele Senni, Morten Schou, Subodh Verma, Adriaan A. Voors, Dirk von Lewinski, Faiez Zannad, Bertram Pitt, Muthiah Vaduganathan, Scott D. Solomon, John J.V McMurray   +23 more
wiley   +1 more source